Dr. Shermaine Tilley is a Managing Partner at CTI Life Sciences Fund, a Montreal-based venture capital fund investing across Canada and the U.S. Since joining CTI LSF at its inception in 2006, Shermaine has played a critical role in each of the Fund’s investments, including Medicago (acquired by Mitsubishi Tanabe for $357M in 2013) as well as Xagenic and Zymeworks. Prior to joining CTI LSF, Dr. Tilley was Senior VP at Drug Royalty Corporation (now DRI), the world’s first private equity firm exclusively focused on royalty transactions in the biotech/pharma space. Before DRC, Dr. Tilley ran and managed a research laboratory, holding faculty positions at the NYU School of Medicine and Public Health Research Institute, NY, and on the PHRI Board of Directors. Concomitantly with her tenure at NYU School of Medicine and PHRI, she consulted for the NIH Small Business Innovation Research (SBIR) program in immunology and infectious diseases for 10 years.
Dr. Tilley holds a Ph.D. in biochemistry from the Johns Hopkins University School of Medicine, an MBA from the University of Toronto, and is a member of the CFA Society of Toronto. She currently sits on the boards of Xagenic, Zymeworks and BIOTECanada, and served as a board observer on Enobia prior to its acquisition by Alexion in 2012 for $1.1B.